Analyst Price Target is $15.17
▲ +534.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rezolute in the last 3 months. The average price target is $15.17, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 534.59% upside from the last price of $2.39.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Rezolute. This Buy consensus rating has held steady for over two years.
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.